EPPIC was founded on March 4, 1998, by a group of Silicon Valley life science professionals who shared both a passion for their industry and a common heritage from the Indian subcontinent. EPPIC's mission is to promote networking, entrepreneurship and mentoring for life science professionals, create US-India life science synergy, and be a resource for industry and academia.
EPPIC is an entirely volunteer-driven non-profit organization run by individuals passionate about making a difference. EPPIC has a number of illustrious scientists and industry leaders as active members who are in synch with the latest ideas, trends, needs and drive the organization’s mission. It is noteworthy that in the past 15 years EPPIC has organized over 50 quarterly networking events and seven annual conferences for the benefit of the life science community, not to mention the numerous start ups and longstanding mentoring relationships that have blossomed out of EPPIC meetings. EPPIC events have attracted sponsorships from well-regarded industry leaders and corporate houses. Industry leaders have endorsed EPPIC events for rich and meaningful science and engineering content and the valuable networking opportunities that EPPIC events create. EPPIC membership is open to all professionals interested in all sectors and functions in the life science industry.
Volunteering at EPPIC »
EPPIC is encouraging motivated individuals who can volunteer with the executive
committee and sub-committees. Volunteering for EPPIC can be rewarding and
educational. If you're interested, please select the "Contact us" button on the
home page and register. Please briefly describe your interests in the space
Creating a Billion Dollar Pharmaceutical Enterprise:
Success Story of Pearl Therapeutics
When: Tuesday, May 6, 2014, 6:00 - 9:00 pm
Where: Cubberley Theater, 4000 Middlefield Road, Palo Alto, CA 94306
Sarvajna Dwivedi, Ph.D., co-founder and Chief Scientific Officer of Pearl Therapeutics, Inc., will describe the scientific, clinical and organizational excellence required to take Pearl from a start-up to a $1.15 B acquisition by AstraZeneca. Listen to the scientific story of inventing a formulation platform, generating a vast amount of clinical evidence in the challenging arena of chronic obstructive pulmonary disease and assembling an organization that prepared three products for Phase III studies within 5 years. Dr. Dwivedi will also describe how Pearl raised its initial capital, recruited top management, implemented a multi-state, multi-site operational model and overcame technical challenges to rapidly progress its products through development. Pearl is now a thriving entity under the AstraZeneca umbrella, with an expanding pipeline and a strong potential to impact indications related to breathing impairment.
EPPIC Members / Charter Members / Sponsors: Complimentary
EPPIC Non-members: $15 (Advance Registration) / $20 (On-site Registration)
Please visit www.eppicglobal.org to learn more about the event and EPPIC.
Sarvajna Dwivedi, Ph.D.
Co-Founder and Chief Scientific Officer, Pearl Therapeutics, Inc.
Dr. Dwivedi, co-founder of Pearl Therapeutics and now CSO of the division at AstraZeneca, has extensive prior experience in drug development at Glaxo, Dura, Alkermes and Nektar. He was involved in the development of over 40 molecules in various therapeutic classes and dosage forms from discovery to commercialization. At Nektar, he served as the Director of Product Development, responsible for new product identification, design, planning and development efforts. At Alkermes, he served as the Director of Delivery Systems, responsible for the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programs. Earlier, at Glaxo, Dr. Dwivedi was involved in the development, manufacturing and approval of Flovent® Diskhaler, Serevent® Diskus, Advair® Diskus, Relenza® Diskhaler and Ventolin® Evohaler. In addition to his product development experience, Dr. Dwivedi has led and conducted technical due diligence efforts for in-licensing, out-licensing and acquisition opportunities. Dr. Dwivedi holds M.Sc. and Ph.D. degrees in Pharmaceutical Sciences from the University of British Columbia and M.Pharm. and B.Pharm.(Hons) from Banaras Hindu University in India.
On behalf EPPIC Board,
We are pleased to announce the appointment of Ravi Mistry as a President-elect (2013) and as a President for 2014-2015 term.
And the election of two new Board members: Mohan Uttarwar (CEO, Oncomdx and former founder and Chariman of BioImagene) and Pradeep Fernandes (Co-founder and President, CellWorks Group).
In order to bring operational excellence to EPPIC and with an objective to take it to next level, EPPIC Board has created a new position, Chief Operating Officer (COO) and we are pleased announce that Chitra Sharma is elected to serve in this role for 2014-2015 term.
EPPIC Video »
Previous Annual Events »
2013: EPPIC Annual Conference 2013, Sunday, January 6, 2013 - New Frontiers in Health Care Sciences [more...]
2012: EPPIC Annual Conference 2012, Sunday, January 8, 2012 - Leveraging Emerging Markets and Technologies in Life Sciences[more...]
2011: EPPIC Annual Conference 2011, Sunday, January 9, 2011 - Partnering Paradigms for Life Sciences [more...]
2010: EPPIC Annual Conference 2010, Sunday, January 10, 2010 - Emerging Trends and Opportunities in Life Sciences [more...]
2009: EPPIC Annual Conference 2009, Sunday, January 11, 2009 - A Passage to Innovation in the Life Sciences [more...]
2008: EPPIC's Biennial Symposium, January 12, 2008 - Life Sciences Business in India- The Next Steps
Interactive Symposium focussed on: Innovative R & D and Follow-on Biologics
The event was a grand success and attracted participants from different continents.
EPPIC Symposium - 2005,
Information and Photographs